News for Neuronetics, Inc. (STIM)

**media[581340]**

Neuronetics' strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth. See why STIM stock is a promising investment.

**media[578950]**

The mean of analysts' price targets for Neuronetics (STIM) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Total Revenue: $22.5 million, an increase of 11% over the fourth quarter of 2023.NeuroStar System Revenue: $3.8 million with 46 systems shipped.U.S. Treatment

Mar 04, 2025 / 01:30PM GMTOperator Good day and thank you for standing by. Welcome to the Neuronetics fourth-quarter 2024 financial and operating results confer

Neuronetics, Inc. (NASDAQ:STIM) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ETCompany ParticipantsMark Klausner - Investor RelationsKeith...

Neuronetics, Inc. (STIM), Tuesday announced financial outlook for the first quarter and fiscal year 2025. The company sees worldwide revenue between $28.0 million and $30.

MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. ( STIM) (the ”œCompany” or ”œNeuronetics”) a vertically integrated, commercial stage,

**media[556688]**

Revenue: Achieved $22.5 million in Q4 2024, surpassing the estimated $19.63 million and marking an 11% increase from Q4 2023.Earnings Per Share (EPS): Reported

Neuronetics (STIM) Q4 results: GAAP EPS misses by $0.09; revenue rises 10.7%. 2025 outlook: $145M-$155M revenue, 55% gross margin.

MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. ( STIM), a commercial stage medical technology company focused on designing, developing, an

**media[556115]**

Neuronetics Inc (STIM) is set to release its Q4 2024 earnings on Mar 4, 2025. The consensus estimate for Q4 2024 revenue is $19.63 million, and the earnings are

**media[535348]**

California-based Conduit Pharmaceuticals Inc. (CDT), a clinical-stage specialty biopharmaceutical company is up over 79 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. ( STIM) (the ”œCompany”) today announced that it has priced its previously announced unde

MALVERN, Pa., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. ( STIM) (the ”œCompany”) today announced that it has commenced an underwritten public off